<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Liver phosphorylase deficiency (glycogen storage disease VI, Hers disease)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Liver phosphorylase deficiency (glycogen storage disease VI, Hers disease)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Liver phosphorylase deficiency (glycogen storage disease VI, Hers disease)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J Craigen, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sihoun Hahn, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>There are a number of inborn errors of glycogen metabolism that result from pathogenic variants in genes for virtually all of the proteins involved in glycogen synthesis, degradation, or regulation. Those disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (GSDs). They have largely been categorized by number according to the chronology of recognition of the responsible enzyme defect (<a class="graphic graphic_table graphicRef54417" href="/d/graphic/54417.html" rel="external">table 1</a>). Liver phosphorylase deficiency (GSD VI; MIM #232700), also known as Hers disease, is usually a mild form of glycogenosis; however, severe hepatomegaly and recurrent severe hypoglycemia have been described [<a href="#rid1">1</a>]. It is due to deficiency of the liver isoform of phosphorylase.</p><p>Liver phosphorylase deficiency is reviewed here. Other GSDs are reviewed separately.</p><p class="headingAnchor" id="H9435862"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Glycogen is the stored form of glucose and serves as a buffer for glucose needs. Glycogen is formed in periods of dietary carbohydrate loading and broken down when glucose demand is high or dietary availability is low (<a class="graphic graphic_figure graphicRef81164" href="/d/graphic/81164.html" rel="external">figure 1</a>).</p><p>Glycogen is most abundant in liver and muscle, which are most affected by disorders of glycogen metabolism. The physiologic importance of a given enzyme in liver and muscle determines the clinical manifestations of the disease. The main role of glycogen in the liver is to store glucose for release to tissues that are unable to synthesize significant amounts during fasting. The major manifestations of disorders of glycogen metabolism affecting the liver are hypoglycemia and hepatomegaly. (See  <a class="medical medical_review" href="/d/html/1808.html" rel="external">"Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus"</a>.)</p><p>A more extensive overview of GSD is presented separately. (See  <a class="medical medical_review" href="/d/html/2941.html" rel="external">"Overview of inherited disorders of glucose and glycogen metabolism"</a>.)</p><p class="headingAnchor" id="H9435888"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of GSD VI is unknown. It is rare in the general population, although it is probably underdiagnosed because of its typically more indolent course compared with other GSDs. GSD VI and IX (deficiencies of liver phosphorylase and the enzyme that regulates its activity, respectively) together account for 25 to 30 percent of all the GSDs, with an estimated prevalence of 1 in 100,000. Most of these are GSD type IX. The disease frequency is 1 in 1000 in a Pennsylvanian Mennonite population with a founder mutation [<a href="#rid2">2</a>]. (See <a class="local">'Genetics'</a> below.)</p><p class="headingAnchor" id="H9435904"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>GSD VI is due to a deficiency of liver phosphorylase. Liver glycogen phosphorylase catalyzes the cleavage of 1,4 glucosidic bonds to release glucose 1-phosphate from glycogen (<a class="graphic graphic_figure graphicRef81164" href="/d/graphic/81164.html" rel="external">figure 1</a>). Enzyme activity is regulated by phosphorylation by phosphorylase kinase, the deficiency of which causes GSD IX. (See  <a class="medical medical_review" href="/d/html/2908.html" rel="external">"Phosphorylase b kinase deficiency"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>GSD VI is an autosomal-recessive disorder. It is caused by pathogenic variants in the gene for the liver isoform of glycogen phosphorylase (PYGL), located at 14q21. Missense, nonsense, and splice-site mutations have been described [<a href="#rid3">3,4</a>], although the frequency of null mutations appears less than other GSDs [<a href="#rid5">5</a>]. A founder mutation involving a splice-site alteration was identified in a Pennsylvanian Mennonite population [<a href="#rid2">2</a>]. Similarly, a common truncating variant was described in South China [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients typically present in early childhood with the characteristic features of growth retardation and prominent hepatomegaly [<a href="#rid7">7</a>]. A case series of 61 patients revealed a median age at diagnosis of 1.8 years, ranging from 5 weeks to 38 years [<a href="#rid8">8</a>]. Thirty-five to 53 percent of patients are reported to have short stature [<a href="#rid8">8,9</a>]. Most have mild hypoglycemia, hyperlipidemia, and ketosis, although occasional patients have more significant hypoglycemia [<a href="#rid5">5</a>]. Hypoglycemia and ketosis typically occur after an overnight fast or after prolonged daytime fasting, such as during an illness, although ketosis can be present in the absence of hypoglycemia, potentially leading to diagnostic errors [<a href="#rid10">10</a>]. Skeletal and cardiac muscle are typically not affected. Intellectual development is normal in most cases. The patient may develop osteoporosis if the disease is untreated. Manifestations improve with puberty, with a decrease in hepatomegaly and improvement in growth with attainment of normal adult height [<a href="#rid1">1</a>]. Early-onset cirrhosis was observed in four children (ages 1.4 to 6.1 years) [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H9435920"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>Patients often have elevated concentrations of serum transaminases and hyperlipidemia. Plasma concentrations of uric acid are elevated in half of patients at the time of diagnosis but usually normalize with treatment. However, increased uric acid level may recur in adolescence and adulthood [<a href="#rid6">6</a>]. Postprandial lactic acidemia is observed. Biotinidase activity is increased and may be a sensitive biomarker [<a href="#rid11">11</a>]. The activity of serum creatine kinase is normal. Unlike GSD type IX, an attenuated rise in glucose is observed following administration of <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a>.</p><p class="headingAnchor" id="H4"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of liver phosphorylase deficiency should be considered in a child with unexplained hepatomegaly and ketosis with elevated transaminases. A fasting glucose and test for ketones should be performed, with the caveat that the child needs to be monitored closely if GSD I is being considered because of the risk of significant hypoglycemia. GSD IX is more common and presents similarly to GSD VI but is primarily X linked. Thus, molecular testing of the gene responsible for GSD VI (<em>PYGL</em>) is done first if the patient is female. Testing of the gene responsible for GSD IX (phosphorylase kinase, liver, alpha-2 subunit [<em>PHKA2</em>]) is done first if the patient is male. The increasing use of multigene panels may make this distinction moot.</p><p>The diagnosis can also be confirmed by reduced or absent enzyme activity in liver tissue, but enzyme activity can be affected by other factors, leading to erroneous results. Assay of enzyme activity for both phosphorylase and phosphorylase b kinase (PBK) may be performed on erythrocytes and leukocytes. However, false negatives (normal enzyme activity detected) are common because the deficiency is isolated to the liver. Thus, molecular testing for <em>PYGL</em> gene mutations is the preferred confirmatory diagnostic tool [<a href="#rid12">12</a>]. For the Mennonite population, it is only necessary to test for the one mutation found specifically in that group (c.1620+1G&gt;A). For others, sequencing of the gene is necessary.</p><p>Liver biopsy with assay of enzyme activity is performed if molecular testing is nondiagnostic.</p><p class="headingAnchor" id="H9435928"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Phosphorylase b kinase (PBK) is necessary for activation of liver glycogen phosphorylase. Thus, PBK deficiency (GSD IX) has a similar clinical presentation to GSD VI. However, the response to <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> is normal in GSD IX, unlike GSD VI. In addition, the majority of cases of PBK deficiency are X linked. (See  <a class="medical medical_review" href="/d/html/2908.html" rel="external">"Phosphorylase b kinase deficiency"</a>.)</p><p>Hypoglycemia is usually more severe in GSD I. In addition, fasting serum lactate is elevated in GSD I and normal in GSD VI. (See  <a class="medical medical_review" href="/d/html/2946.html" rel="external">"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)"</a>.)</p><p>GSD III presents with hypoglycemia and hepatomegaly, but most of these children also have skeletal muscle weakness associated with an elevated serum creatinine kinase (CK). (See  <a class="medical medical_review" href="/d/html/2906.html" rel="external">"Glycogen debrancher deficiency (glycogen storage disease III, Cori disease)"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Patients with hypoglycemia should have frequent, small meals and increased protein intake (2 to 3 g/kg/day) [<a href="#rid13">13</a>]. Alternatively, uncooked cornstarch can be used at a dose of 1 to 2 g/kg per dose, between meals and at bedtime. The bedtime dose is generally higher than the between meal doses. Young infants (under six months of age) may develop gastrointestinal distress (colicky symptoms or diarrhea) with cornstarch administration because pancreatic amylase has not reached a normal adult level. Preprandial glucose monitoring is useful in adjusting therapy. Treatment with cornstarch may improve growth, hepatomegaly, bone density, serum analytes, and stamina due to better metabolic control, even in patients without hypoglycemic episodes [<a href="#rid1">1</a>]. A pregnant individual with GSD VI should have their blood glucose monitored. Bone density testing should be assessed once the individual has stopped growing [<a href="#rid1">1</a>]. Published guidelines for the diagnosis and management of GSD VI are available [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H9435896"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The disease typically has a benign course and improves with age, although hypoglycemia can occur during pregnancy [<a href="#rid1">1</a>]. Hepatomegaly resolves in most cases. Patients may be at increased risk for developing hepatic tumors [<a href="#rid14">14,15</a>]. Liver ultrasound to screen for hepatic adenoma should be performed annually beginning around 10 years of age.</p><p class="headingAnchor" id="H9435936"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – Liver phosphorylase deficiency, also called glycogen storage disease type VI (GSD VI), is caused by pathogenic variants in the gene for the liver isoform of glycogen phosphorylase (PYGL) (<a class="graphic graphic_figure graphicRef81164" href="/d/graphic/81164.html" rel="external">figure 1</a>). (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Patients typically present in early childhood with the characteristic features of growth retardation, prominent hepatomegaly, mild hypoglycemia, and ketosis (<a class="graphic graphic_table graphicRef54417" href="/d/graphic/54417.html" rel="external">table 1</a>). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Molecular testing for <em>PYGL</em> gene mutations is the preferred confirmatory diagnostic tool. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Phosphorylase b kinase (PBK) deficiency (GSD IX) has a similar clinical presentation to GSD VI. However, the response to <a class="drug drug_general" data-topicid="8493" href="/d/drug information/8493.html" rel="external">glucagon</a> is normal in GSD IX, unlike GSD VI. (See <a class="local">'Differential diagnosis'</a> above and <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Patients are treated with uncooked cornstarch between meals and at bedtime to prevent hypoglycemia and ketosis, in addition to a high-protein diet. Treatment may improve growth, hepatomegaly, bone density, serum analytes, and stamina. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The disease typically has a benign course and improves with age. However, patients may be at increased risk for hepatic tumors. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Labrador E, Weinstein DA. Glycogen Storage Disease Type VI. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, 2019.</li><li><a class="nounderline abstract_t">Chang S, Rosenberg MJ, Morton H, et al. Identification of a mutation in liver glycogen phosphorylase in glycogen storage disease type VI. Hum Mol Genet 1998; 7:865.</a></li><li><a class="nounderline abstract_t">Burwinkel B, Bakker HD, Herschkovitz E, et al. Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI. Am J Hum Genet 1998; 62:785.</a></li><li><a class="nounderline abstract_t">Tang NL, Hui J, Young E, et al. A novel mutation (G233D) in the glycogen phosphorylase gene in a patient with hepatic glycogen storage disease and residual enzyme activity. Mol Genet Metab 2003; 79:142.</a></li><li><a class="nounderline abstract_t">Beauchamp NJ, Taybert J, Champion MP, et al. High frequency of missense mutations in glycogen storage disease type VI. J Inherit Metab Dis 2007; 30:722.</a></li><li><a class="nounderline abstract_t">Luo X, Duan Y, Fang D, et al. Diagnosis and follow-up of glycogen storage disease (GSD) type VI from the largest GSD center in China. Hum Mutat 2022; 43:557.</a></li><li class="breakAll">Kishnani PS, Chen YT. Disorders of glycogen metabolism. In: Rudolph’s Pediatrics, 23rd ed, Kline MW (Ed), McGraw-Hill, 2018.</li><li><a class="nounderline abstract_t">Grünert SC, Hannibal L, Spiekerkoetter U. The Phenotypic and Genetic Spectrum of Glycogen Storage Disease Type VI. Genes (Basel) 2021; 12.</a></li><li><a class="nounderline abstract_t">Roscher A, Patel J, Hewson S, et al. The natural history of glycogen storage disease types VI and IX: Long-term outcome from the largest metabolic center in Canada. Mol Genet Metab 2014; 113:171.</a></li><li><a class="nounderline abstract_t">Hoogeveen IJ, van der Ende RM, van Spronsen FJ, et al. Normoglycemic Ketonemia as Biochemical Presentation in Ketotic Glycogen Storage Disease. JIMD Rep 2016; 28:41.</a></li><li><a class="nounderline abstract_t">Paesold-Burda P, Baumgartner MR, Santer R, et al. Elevated serum biotinidase activity in hepatic glycogen storage disorders--a convenient biomarker. J Inherit Metab Dis 2007; 30:896.</a></li><li><a class="nounderline abstract_t">Davit-Spraul A, Piraud M, Dobbelaere D, et al. Liver glycogen storage diseases due to phosphorylase system deficiencies: diagnosis thanks to non invasive blood enzymatic and molecular studies. Mol Genet Metab 2011; 104:137.</a></li><li><a class="nounderline abstract_t">Kishnani PS, Goldstein J, Austin SL, et al. Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2019; 21:772.</a></li><li><a class="nounderline abstract_t">Ogawa A, Ogawa E, Yamamoto S, et al. Case of glycogen storage disease type VI (phosphorylase deficiency) complicated by focal nodular hyperplasia. Pediatr Int 2010; 52:e150.</a></li><li><a class="nounderline abstract_t">Manzia TM, Angelico R, Toti L, et al. Glycogen storage disease type Ia and VI associated with hepatocellular carcinoma: two case reports. Transplant Proc 2011; 43:1181.</a></li></ol></div><div id="topicVersionRevision">Topic 2944 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Labrador E, Weinstein DA. Glycogen Storage Disease Type VI. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al (Eds), University of Washington, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9536091" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Identification of a mutation in liver glycogen phosphorylase in glycogen storage disease type VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9529348" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12809646" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A novel mutation (G233D) in the glycogen phosphorylase gene in a patient with hepatic glycogen storage disease and residual enzyme activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17705025" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : High frequency of missense mutations in glycogen storage disease type VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35143115" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Diagnosis and follow-up of glycogen storage disease (GSD) type VI from the largest GSD center in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35143115" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnosis and follow-up of glycogen storage disease (GSD) type VI from the largest GSD center in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34440378" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Phenotypic and Genetic Spectrum of Glycogen Storage Disease Type VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25266922" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The natural history of glycogen storage disease types VI and IX: Long-term outcome from the largest metabolic center in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26526422" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Normoglycemic Ketonemia as Biochemical Presentation in Ketotic Glycogen Storage Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17994282" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Elevated serum biotinidase activity in hepatic glycogen storage disorders--a convenient biomarker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21646031" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Liver glycogen storage diseases due to phosphorylase system deficiencies: diagnosis thanks to non invasive blood enzymatic and molecular studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30659246" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20723115" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Case of glycogen storage disease type VI (phosphorylase deficiency) complicated by focal nodular hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21620082" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Glycogen storage disease type Ia and VI associated with hepatocellular carcinoma: two case reports.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
